00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in...
22:10 , Aug 3, 2018 |  BC Extra  |  Politics & Policy

ICER announces preliminary 2019 topics

The Institute for Clinical and Economic Review (ICER) released Thursday a preliminary list of drugs and other healthcare interventions that it may review in 2019. ICER's selection criteria include the projected timing and likelihood of...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample, cell culture and mouse studies suggest inhibiting PCBP1 could help treat MS. In brain tissue samples from MS patients, PCBP1 expression was higher in MS lesions than in matched normal...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Company News

Neuro play Convelo emerges from stealth

Convelo Therapeutics Inc. (Cleveland, Ohio) emerged from stealth mode and will discover and develop candidates to treat neurological diseases including multiple sclerosis (MS). The biotech is developing products that regenerate myelin. The company also announced a...
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology; autoimmune disease

INDICATION: Alzheimer’s disease (AD); multiple sclerosis (MS); rheumatoid arthritis (RA) Patient sample, in vitro, cell culture and mouse studies identified a peptide-based inhibitor of the MYD88-TLR2 interaction that could help treat AD, MS, and RA. In...
17:31 , Jul 20, 2018 |  BC Week In Review  |  Financial News

MS play Octave adds Scangos to board, raises $14M series A

Multiple sclerosis company Octave Bioscience Inc. (Menlo Park, Calif.) raised $14 million on July 12 in a series A round led by new investor BlueCross BlueShield Venture Partners. Echo Health Ventures, Section 32 and other...
16:42 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18...
19:59 , Jul 18, 2018 |  BC Extra  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings. On...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
18:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

NICE does not recommend Roche's ocrelizumab for primary progressive MS

The U.K.'s NICE said in an appraisal consultation it does not recommend the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis (MS) with imaging features characteristic of inflammatory activity...